Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 12/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366221 | 0.82 | PSMB5 (0.36) | CASP1CASP3MMEECE1LMNA | |
| SCHEMBL23366189 | 0.82 | PSMB5 (0.36) | CASP1CASP3MMEECE1LMNA | |
| SCHEMBL13525028 | 0.81 | MME (0.57) | GAAMAPTMMELMNATDP1 | |
| SCHEMBL24180261 | 0.80 | PSMB5 (0.34) | CASP1CASP3GAAMMEECE1 | |
| SCHEMBL22181834 | 0.79 | GAA (0.52) | CASP1GAAMAPTMMEECE1 | |
| SCHEMBL23366239 | 0.78 | CTSS (0.35) | — | |
| SCHEMBL23366183 | 0.77 | SMN1; SMN2 (0.52) | GAALMNATDP1 | |
| SCHEMBL554032 | 0.76 | CASP1 (0.67) | CASP1MMEECE1 | |
| SCHEMBL376886 | 0.76 | CASP1 (0.67) | CASP1MMEECE1 | |
| SCHEMBL613386 | 0.76 | CASP1 (0.67) | CASP1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377487-B1 | COMPOUNDS FOR MEDICINAL APPLICATIONS | AusVir Therapeutics Pty Ltd (AU) | 2022-01-12 | — | — | EP | disclosed |
| US-11007274-B2 | Compounds for medicinal applications | AusVir Therapeutics Pty Ltd (AU) | 2021-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007274-B2 | Compounds for medicinal applications | HAVCR2, ENGASE, DNPEP | CASP1 2204/4885CASP3 1240/4885GAA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.